NICE issues Medtech Innovation Briefing on PredictSURE IBD™
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
Investors invited to discover the next big thing in life science and med-tech
Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
PredictImmune wins Business Weekly Life Science Innovation (Product) award
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.
ImmunoBiology Ltd enters licensing agreement with China's largest vaccine producer
Cambridge-based vaccine company ImmunoBiology Ltd (ImmBio) has entered a licensing agreement with the largest vaccine producer in China, CNBG, to co-develop ImmBio’s PnuBioVax Vaccine against pneumococcal infection.
Apply to present at the 2019 Babraham Investor Conference
The Babraham Investor Conference (BIC) is back to bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities. Now, companies seeking funding of between £250K to £20M have the opportunity to pitch to an audience of potential investors on 15 May at the Babraham Research Campus, Cambridge.
PredictImmune's first product enters NICE Diagnostic Assessment Programme
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the formal entry of its first product, PredictSURE IBD™, into NICE’s Diagnostic Assessment Programme (DAP).
Apply to present at the Babraham Investor Conference 2019
Now in its 9th year, the Babraham Investor Conference 2019 (BIC 2019) is a must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe.
Applications open for second Accelerate@Babraham life-science start-up competition
Life science start-ups are invited to apply for the opportunity to win access to the Babraham Research Campus bio-incubator facilities, plus an extended programme of support and mentoring.
PredictImmune announces issuance of new US patent in support of commercialisation
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk.
PredictImmune and the Crohn’s & Colitis Foundation announce a joint study
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation. The study is expected to advance progress towards personalised medicine for inflammatory bowel disease (IBD) patients in the US.
Mission Therapeutics appoints Dr Nick Edmunds to VP, Head of DUB Discovery
Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.
Mission Therapeutics and AbbVie sign DUBs collaboration in Alzheimer’s and Parkinson’s
Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities
Cambridge drug screening team shares in £1.3m investment backing
Venture capital firm Par Equity has invested £1.3m in a rapidly growing stem-cell research company that is helping pharmaceutical giants to develop new treatments for diseases including Parkinson’s and Alzheimer’s.
PredictImmune invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, announced today that it has been invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit, taking place in Newark, NJ, USA on 17th and 18th October 2018.
Accelerate@Babraham attracts additional support from Taylor Vinters and Silicon Valley Bank
The Babraham Research Campus is delighted to announce Taylor Vinters and Silicon Valley Bank as the latest organisations to pledge support for the Babraham Research Campus’ life-science accelerator, Accelerate@Babraham.
Accelerate@Babraham Start-up Competition: winners announced
Five science start-ups have been awarded £20k and access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham
Accelerate@Babraham start-up competition: short-listed finalists announced
Eight life science start-ups will pitch head-to-head next week (11th July) to win access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham.
PredictImmune appoints new CEO
PredictImmune, a developer of pioneering prognostic products for guiding treatment options and improving patient outcomes in immune-mediated diseases, has announced the appointment of Paul Kinnon as its new Chief Executive Officer.
Babraham Research Campus launches start-up competition, Accelerate@Babraham
Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities, plus an additional programme of support from a host of experienced life science academic and commercial experts, including new strategic partner, Eli Lilly.
New bio-incubator and life-science accelerator capability launches at Babraham
A new bio-incubator and life science accelerator capability has been launched at the Babraham Research Campus. Accelerate@Babraham is supported by AstraZeneca, MedImmune, One Nucleus, and RxCelerate.
Bicycle Therapeutics secures Innovate UK grant to develop the next generation of antibiotics
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.
Babraham Bioscience Technologies' Technology Development Laboratory moves to Abzena
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited, (BBT) the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).
Mission Therapeutics appoints Scientific Advisory Board
Mission Therapeutics, a Babraham-based drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
Bioconjugation specialist Innova Biosciences acquired by SYGNIS AG
Madrid, Spain, Heidelberg, Germany, and Cambridge, UK...Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.
Babraham Conference attracts over 120 investors focused on life science and med-tech
Held at The Babraham Research Campus, the annual Babraham Investor Conference (BIC) gave scale-up and venture-stage growth companies seeking Seed to Series C funding, the opportunity to showcase their science to investors actively seeking further investment opportunities.